In patients on AFH therapeutic system for BPH, its co-administration with TDF showed the greatest improvement of both BPH and erectile dysfunction symptoms compared with single-dose therapy with either an alpha-1 receptor antagonist or a PDE inhibitor [12,14]. The gene discussed is ALDH7A1; the disease is benign prostatic hyperplasia.